Reference is made to the stock exchange release from Gentian 
Diagnostics AS ("Gentian" or the "Company") published 
yesterday regarding the contemplated private placement of up 
to NOK 100 million by issuance of up to 2,857,143 new shares 
at NOK 35 per share (the "Private Placement").

The application period in Tranche 2 expired at 14:00 CET 
today, 27 January 2017. Tranche 2 was fully subscribed and 
in total 142,857 new shares were allocated at NOK 35 per 
share (corresponding to NOK 4,999,995 in gross proceeds). 
Total number of shares placed in Tranche 1 and Tranche 2 of 
the Private Placement is hence 2,857,143, corresponding to 
gross proceeds of NOK 100,000,005.

In connection with the Private Placement Tranche 2, the 
following primary insider has been allocated for shares in 
Gentian Diagnostics AS:
	
Vice President of Marketing and Sales, Catherine Townsley.

Details on the transaction:

Date of the transaction: 27.01.2017
Nummber os shares before trade: 13 760
Number of share aquired: 1 000
Number of shares after the trade: 14 760
Share price: NOK 35

Allocation of the new shares is conditional on the Private 
Placement being completed. Completion of the Private 
Placement is subject to, inter alia, approval of the 
company's extraordinary general meeting in a meeting 
expected to be held 30 January 2017.

This notification is given according to Merkur Market's 
continuing obligations section 6.2.
